CMT Research Foundation

Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.

ReviR Therapeutics is a genomics-focused company that specializes in the development of RNA therapeutics aimed at treating cancer, rare genetic disorders, and infectious diseases. The company utilizes an artificial intelligence-driven platform to enhance the discovery of novel RNA-targeting medicines, thereby facilitating the delivery of innovative therapies to a wide patient population. ReviR Therapeutics combines advanced computational techniques with its expertise in RNA biology, positioning itself as a leader in the evolving field of RNA-based therapeutics.

Asha Therapeutics is a biotechnology company focused on developing innovative treatments for neurodegenerative diseases such as Parkinson's Disease, Alzheimer's Disease, Myalgic Encephalomyelitis, and Chronic Fatigue Syndrome. The company employs a mito-centric approach, emphasizing the restoration of cellular function by re-engineering the cellular machinery, which is crucial for maintaining the health of neurons. Asha Therapeutics utilizes its proprietary PRISM™ technology, which combines computational chemistry and neurobiology to design and develop novel small molecule drugs. This platform enables the company to create promising therapeutic candidates targeting neurological disorders, cancer, and infectious diseases, with several candidates advancing toward clinical trials.